David Thomson, Executive Vice President, General Counsel, and Secretary at MANNKIND CORP (NASDAQ:MNKD), reported the sale of company stock totaling $97,641. The transaction involved 24,109 shares of common stock on July 17, 2026, at a weighted average price of $4.05 per share. The shares were sold within a price range of $3.98 to $4.13, and the sale was conducted pursuant to a Rule 10B5-1 trading plan established on December 2, 2025. The stock currently trades at $4.03 with a market capitalization of $1.25 billion, and according to InvestingPro analysis, appears undervalued relative to its Fair Value.
Prior to the sale, on July 15, 2026, Mr. Thomson acquired 93,790 shares of MannKind common stock through the vesting of a Performance Restricted Stock Unit (RSU) award. This award, granted on May 25, 2023, vested upon the achievement of specific performance objectives, including the company’s stock closing price on June 30, 2026, not being less than its price on May 25, 2023, and MannKind’s total shareholder return (TSR) being at the 41.5th percentile of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. The performance objective was met at 83% of the target, resulting in the delivery of these shares, while 19,210 shares were forfeited. InvestingPro Tips highlight that analysts predict the company will be profitable this year, with 7 additional exclusive tips available to subscribers.
Also on July 15, 2026, in connection with the RSU vesting, Mr. Thomson disposed of a total of 98,426 shares of common stock valued at $402,562. These dispositions, occurring at a price of $4.09 per share, were for the payment of tax liabilities by delivering or withholding securities, a common practice incident to the vesting of restricted stock units.
Following these reported transactions, Mr. Thomson directly owns 797,554 shares of MANNKIND CORP common stock.
In other recent news, MannKind Corporation reported a 15% year-over-year revenue increase for the first quarter of 2026, totaling $90 million. This growth was attributed to the addition of FUROSCIX revenues following the acquisition of scPharmaceuticals. However, MannKind posted a non-GAAP net loss of $0.02 per share, which fell short of the forecasted EPS of -$0.01. Additionally, MannKind announced the completion of patient randomization in its U.S. Phase 1b INFLO-1 clinical trial and the enrollment of the first patient in its global Phase 2 INFLO-2 study for nintedanib DPI. The company plans to report data from the INFLO-1 study in the third quarter of 2026. Furthermore, the U.S. Food and Drug Administration approved MannKind’s Afrezza inhaled insulin for children and adolescents aged 6 and older with type 1 and type 2 diabetes. At its 2026 Annual Meeting of Stockholders, MannKind elected all nine director nominees to serve until the next annual meeting.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
